| Name | Title | Contact Details |
|---|
DESTINATION DEVELOPMENT Understanding what exists in your destination is important. Knowledge of your cannabis and hemp-related assets directly informs the strategy and program architecture. I engage and educate stakeholders, assess the destination, and develop a bespoke cannabis travel strategy and program that fosters long term success. The strategy may or may not include B2C product development i.e. trail, passport, newsletter. DESTINATION MARKETING The data shows that the cannabis-motivated active leisure travel audience is a high value audience that stays longer and spends more while in a destination. Through a dedicated cannabis travel program, I work with stakeholders to facilitate a steady flow of cannabis and hemp-related content that elevates the cannabis experience story in a sophisticated and brand aligned way. I advise DMOs on B2B and B2C content and marketing strategies. HOTEL SOLUTIONS Hotels are the heart of the travel ecosystem of a destination. Hotels greatly influence the overall experience for visitors. With a focus on guest experience, room nights, and turn-key incremental revenue opportunities, I help hotels understand, prepare for, and serve the cannabis and hemp CBD-interested hotel guest. Solutions include hospitality education, frontline staff support, and revenue generating opportunities in lobby, spa, and in-room.
Big Brand Tire & Service is a tire and automotive service retailer founded in 1969 in Moorpark, California. With over 215 locations across six states, primarily in the Southwest US, it ranks among the top 10 largest tire dealerships in the country. The company was acquired by Percheron Capital in 2021, which has fueled its rapid expansion through multiple acquisitions. The company specializes in a wide range of tire and automotive maintenance services. It offers major tire brands such as Bridgestone, Michelin, and Goodyear, along with services including tire sales, wheel alignment, oil changes, brake inspections, and full-service auto repair. Big Brand Tire & Service emphasizes customer satisfaction and aims to be a reliable one-stop shop for tire and auto repair needs. The company is committed to maintaining its locally owned heritage while focusing on long-term growth and community support.
BLUEBONNET® Abstract and Title is a locally owned and operated title company located in Brenham and Bellville Texas and serving adjacent counties. We are fully licensed in Washington, Austin, Fayette, Brazos, Grimes, Robertson, Colorado, and Lee Counties, and serve the adjoining counties (such as Waller), regularly. BLUEBONNET® was established to provide a title company focused on the customer and the community. BLUEBONNET® sets itself apart from its competitors by providing excellent customer service in all aspects of the real estate transaction. Our customers actually enjoy the real estate closing process – we know you will too.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.